scispace - formally typeset
L

Luisa Verga

Researcher at University of Milano-Bicocca

Publications -  45
Citations -  795

Luisa Verga is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 11, co-authored 31 publications receiving 458 citations. Previous affiliations of Luisa Verga include University of Milan.

Papers
More filters
Journal ArticleDOI

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).

Livio Pagano, +119 more
- 14 Oct 2021 - 
TL;DR: In this paper, the authors studied the risk factors for adverse outcomes in patients with hematological malignancies (HM) who developed COVID-19 and analyzed predictors of mortality.
Journal ArticleDOI

Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.

Paolo Perseghin, +13 more
- 01 Aug 2009 - 
TL;DR: The fate of those who failed a first mobilization and subsequently underwent a second attempt or alternative therapeutic approaches was investigated, including time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF).
Journal ArticleDOI

Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

Livio Pagano, +25 more
- 01 Dec 2012 - 
TL;DR: Although this study was not randomized, it demonstrates in a real-life setting that posaconazole prophylaxis confers an advantage in terms of both breakthrough IFDs and overall survival compared to itraconazoles propedylaxis.
Journal ArticleDOI

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)

Morena Caira, +43 more
- 01 Feb 2015 - 
TL;DR: Several hospital-independent variables could potentially influence the onset of invasive mold infections in patients with newly diagnosed acute myeloid leukemia after their first course of chemotherapy.
Journal ArticleDOI

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

Oliver A. Cornely, +20 more
- 01 Aug 2017 - 
TL;DR: The IFD rate among adult patients undergoing remission-induction chemotherapy for newly diagnosed ALL was 11.7% in the placebo group, and was not significantly different in patients receiving L-AMB, suggesting that the L- AMB regimen studied is not effective as prophylaxis against IFD.